{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T22:43:08Z","timestamp":1768257788987,"version":"3.49.0"},"reference-count":13,"publisher":"Tohoku University Medical Press","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2021]]},"DOI":"10.1620\/tjem.255.57","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T22:08:51Z","timestamp":1632780531000},"page":"57-60","source":"Crossref","is-referenced-by-count":3,"title":["Ustekinumab as the First Biological Agent for Crohn\u2019s Disease in a 10-Year-Old Girl"],"prefix":"10.1620","volume":"255","author":[{"given":"Yuji","family":"Fujita","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Dokkyo Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Sugaya","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Dokkyo Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanao","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Dokkyo Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Tominaga","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Dokkyo Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigemi","family":"Yoshihara","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Dokkyo Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"622","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Biancone, L., Onali, S., Petruzziello, C., Calabrese, E. &amp; Pallone, F.(2015)  Cancer and immunomodulators in inflammatory bowel diseases.  <i>Inflamm. Bowel Dis<\/i>., 21, 674-698.","DOI":"10.1097\/MIB.0000000000000243"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Chavannes, M., Martinez-Vinson, C., Hart, L., Kaniki, N., Chao, C.Y., Lawrence, S., Jacobson, K., Hugot, J.P., Viala, J., Deslandres, C., Jantchou, P. &amp; Seidman, E.G.(2019)  Management of paediatric patients with medically refractory crohn\u2019s disease using ustekinumab: a multi-centred cohort study.  <i>J. Crohns Colitis<\/i>, 13, 578-584.","DOI":"10.1093\/ecco-jcc\/jjy206"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Dayan, J.R., Dolinger, M., Benkov, K., Dunkin, D., Jossen, J., Lai, J., Phan, B.L., Pittman, N. &amp; Dubinsky, M.C.(2019)  Real world experience with ustekinumab in children and young adults at a tertiary care pediatric inflammatory bowel disease center.  <i>J. Pediatr. Gastroenterol. Nutr<\/i>., 69, 61-67.","DOI":"10.1097\/MPG.0000000000002362"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Feagan, B.G., Sandborn, W.J., Gasink, C., Jacobstein, D., Lang, Y., Friedman, J.R., Blank, M.A., Johanns, J., Gao, L.L., Miao, Y., Adedokun, O.J., Sands, B.E., Hanauer, S.B., Vermeire, S., Targan, S.,  et al.(2016)  Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease.  <i>N. Engl. J. Med<\/i>., 375, 1946-1960.","DOI":"10.1056\/NEJMoa1602773"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Gomollon, F., Dignass, A., Annese, V., Tilg, H., Van Assche, G., Lindsay, J.O., Peyrin-Biroulet, L., Cullen, G.J., Daperno, M., Kucharzik, T., Rieder, F., Almer, S., Armuzzi, A., Harbord, M., Langhorst, J.,  et al.(2017)  3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: part 1: diagnosis and medical management.  <i>J. Crohns Colitis<\/i>, 11, 3-25.","DOI":"10.1093\/ecco-jcc\/jjw168"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Matsumoto, T., Motoya, S., Watanabe, K., Hisamatsu, T., Nakase, H., Yoshimura, N., Ishida, T., Kato, S., Nakagawa, T., Esaki, M., Nagahori, M., Matsui, T., Naito, Y., Kanai, T., Suzuki, Y.,  et al.(2016)  Adalimumab monotherapy and a combination with azathioprine for Crohn\u2019s disease: a prospective, randomized trial.  <i>J. Crohns Colitis<\/i>, 10, 1259-1266.","DOI":"10.1093\/ecco-jcc\/jjw152"},{"key":"7","unstructured":"Papp, K., Gottlieb, A.B., Naldi, L., Pariser, D., Ho, V., Goyal, K., Fakharzadeh, S., Chevrier, M., Calabro, S., Langholff, W. &amp; Krueger, G.(2015)  Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).  <i>J. Drugs Dermatol<\/i>., 14, 706-714."},{"key":"8","doi-asserted-by":"crossref","unstructured":"Takeuchi, I., Arai, K., Kyodo, R., Sato, T., Tokita, K., Hirano, Y. &amp; Shimizu, H.(2021)  Ustekinumab for children and adolescents with inflammatory bowel disease at a tertiary children\u2019s hospital in Japan.  <i>J. Gastroenterol. Hepatol<\/i>., 36, 125-130.","DOI":"10.1111\/jgh.15128"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Tominaga, K., Sugaya, T., Tanaka, T., Kanazawa, M., Iijima, M. &amp; Irisawa, A.(2021)  Thiopurines: recent topics and their role in the treatment of inflammatory bowel diseases.  <i>Front. Pharmacol<\/i>., 11, 582291.","DOI":"10.3389\/fphar.2020.582291"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Turner, D., Griffiths, A.M., Walters, T.D., Seah, T., Markowitz, J., Pfefferkorn, M., Keljo, D., Waxman, J., Otley, A., LeLeiko, N.S., Mack, D., Hyams, J. &amp; Levine, A.(2012)  Mathematical weighting of the pediatric Crohn\u2019s disease activity index (PCDAI)  and comparison with its other short versions.  <i>Inflamm. Bowel Dis<\/i>., 18, 55-62.","DOI":"10.1002\/ibd.21649"},{"key":"11","doi-asserted-by":"crossref","unstructured":"VanDussen, K.L., Stojmirovic, A., Li, K., Liu, T.C., Kimes, P.K., Muegge, B.D., Simpson, K.F., Ciorba, M.A., Perrigoue, J.G., Friedman, J.R., Towne, J.E., Head, R.D. &amp; Stappenbeck, T.S.(2018)  Abnormal small intestinal epithelial microvilli in patients with Crohn\u2019s disease.  <i>Gastroenterology<\/i>, 155, 815-828.","DOI":"10.1053\/j.gastro.2018.05.028"},{"key":"12","doi-asserted-by":"crossref","unstructured":"van Rheenen, P.F., Aloi, M., Assa, A., Bronsky, J., Escher, J.C., Fagerberg, U.L., Gasparetto, M., Gerasimidis, K., Griffiths, A., Henderson, P., Koletzko, S., Kolho, K.L., Levine, A., van Limbergen, J., Martin de Carpi, F.J.,  et al. (2020)  The medical management of paediatric Crohn\u2019s disease: an ECCO-ESPGHAN guideline update.  <i>J. Crohns Colitis<\/i>, 15, 171-194.","DOI":"10.1093\/ecco-jcc\/jjaa161"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Zittan, E., Kelly, O.B., Kirsch, R., Milgrom, R., Burns, J., Nguyen, G.C., Croitoru, K., Van Assche, G., Silverberg, M.S. &amp; Steinhart, A.H. (2016) Low fecal calprotectin correlates with histological remission and mucosal healing in ulcerative colitis and colonic Crohn\u2019s disease. <i>Inflamm. Bowel Dis<\/i>., 22, 623-630.","DOI":"10.1097\/MIB.0000000000000652"}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/255\/1\/255_57\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T04:48:48Z","timestamp":1633150128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/255\/1\/255_57\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.255.57","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]}}}